Targets › BCL2L1
6 programs from 5 companies in 14 trials: 12 Phase 1, 1 Phase 3, 1 Phase 2; Oncology; next expected readout Dec 2026.
Potent inhibitor of cell death. Inhibits activation of caspases. (UniProt, Q07817)
Open in Phaseline: the race on BCL2L1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| AbbVie | Navitoclax Apoptosis regulator Bcl-2 inhibitor; Apoptosis regulator Bcl-X inhibitor; Apoptosis regulator Bcl-W inhibitor | BCL2, BCL2L1, BCL2L2, BCL2L2-PABPN1 | Phase 3 | Myelofibrosis (MF); Myeloproliferative Neoplasm; Mantle Cell Lymphoma Refractory; High Grade Serous Carcinoma … | Dec 2026 |
| National Cancer Institute (NCI) | Pelcitoclax Bcl-2/Bcl-XL inhibitor | BCL2, BCL2L1 | Phase 1 | Advanced Endometrial Carcinoma | Feb 2027 |
| Elizabeth Stover, MD, PhD | DT2216 BCL-XL proteolysis-targeting chimera (PROTAC) degrader | BCL2L1 | Phase 1 | Ovarian Cancer | Jun 2027 |
| Chia Tai Tianqing Pharmaceutical Group | TQB3142 for injection BCL-XL inhibitor | BCL2L1 | Phase 1 | Advanced Malignant Tumors | Dec 2027 |
| AbbVie | Surzetoclax BCL2 family protein inhibitor | BCL2L1 | Phase 1 | Multiple Myeloma | Dec 2030 |
| Ascentage Pharma Group | APG-1252 BCL-2 family protein inhibitor | BCL2, BCL2L1, BCL2L2, MCL1 | Phase 1 | EGFR Positive Non-small Cell Lung Cancer | – |
Multiple Myeloma (1) Advanced Malignant Tumors (1) Advanced Endometrial Carcinoma (1) Ovarian Cancer (1) Myelofibrosis (MF) (1) Myeloproliferative Neoplasm (1) Mantle Cell Lymphoma Refractory (1) High Grade Serous Carcinoma (1) Myeloid Malignancy (1) Refractory Acute Lymphoblastic Leukemia (1) Recurrent Acute Myeloid Leukemia (1) Metastatic Malignant Solid Neoplasm (1)
small molecule (5), mixed (1)
AbbVie (2) Chia Tai Tianqing Pharmaceutical Group (1) National Cancer Institute (NCI) (1) Elizabeth Stover, MD, PhD (1) Ascentage Pharma Group (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.